Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 3OTHER 2NIH 1NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 3Sarcoma 2CNS 2Thoracic 1Other hematologic neoplasm 1Lymphoid 1Head & Neck 1Gynecologic 1Endocrine 1Dermatologic 1

Conditions

Multiple Endocrine Neoplasia Type 2b 1Multiple Endocrine Neoplasia Type 2a 1Multiple Endocrine Neoplasia 1Carcinoma, Medullary 1

Interventions

Magnetic Resonance Spectroscopy 17Specimen Handling 13lutetium Lu 177 dotatate 7gallium Ga 68 dotatate 7Cisplatin 7cabozantinib 6pazopanib 5Sorafenib 5Fluorodeoxyglucose F18 5Everolimus 5Etoposide 4romidepsin 3olaparib 3fluorodopa F 18 3cixutumumab 3X-Rays 3Temozolomide 3Sunitinib 3Radiotherapy 3Nivolumab 3Ipilimumab 3Iodine-131 3CTLA-4 Antigen 32-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole 3tipifarnib 2belinostat 2aldesleukin 2aflibercept 2Vorinostat 2Trastuzumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × vandetanib × Endocrine × Clear all
NCT00514046 2020-12-22

Vandetanib to Treat Children and Adolescents With Medullary Thyroid Cancer

National Institutes of Health Clinical Center (CC)

Phase 1/2 Completed
17 enrolled 25 charts
Endocrine

Multiple Endocrine Neoplasia, Carcinoma, Medullary, Multiple Endocrine Neoplasia Type 2a, Multiple Endocrine Neoplasia Type 2b

Data powered by HemOnc (CC BY 4.0) Colophon âš¡